RPM Insiders Sell Into 6% Rally as Options Defensiveness Peaks
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
RPM International gained 5.8% on July 22. Eight insiders used that strength to sell. Options traders, meanwhile, are hedging at the highest rate in 52 weeks.
The CEO sold $400K worth of stock on July 17. The CFO sold the same day. So did the EVP, the Chief Accounting Officer, the Chief Compliance Officer, and the Treasurer. The cluster covered eight executives in a single session at $105.08 — just days before the stock's big move to $107.43.
Options Traders Push Defensiveness to a Year High
The put/call ratio has since climbed to 0.2949. That sits 3.5 standard deviations above the 20-day mean of 0.195 — the highest z-score in 52 weeks. This is an escalation from the 3.4 z-score flagged after the July 22 Q4 print, itself already a record reading. Traders who watched the stock drop to $101.53 on earnings before bouncing sharply are now paying more actively for downside protection ahead of the July 24 call.
The stock's one-month return remains essentially flat, down 0.5%. The whipsaw — down nearly 6% after Q4, then back up 5.8% in a day — has left options traders on edge.
Borrow Market Calm, Cost Ticking Up
Short sellers are not behind the hedging anxiety. SI has fallen 16% in one week to 2.8% of the float. Borrow availability is extraordinarily loose at 7,757% — meaning there are roughly 78 shares available to lend for every one already borrowed. The lending market is not under any meaningful stress.
Cost to borrow has ticked up 56% over the week to 0.45%. That sounds dramatic. In absolute terms, it remains negligible for a name this easy to borrow. The directional move is worth watching, but context matters.
Analyst Targets Still Well Above Current Price
The consensus price target sits at $129.57 — 21% above yesterday's close of $107.43. The most recent move was BMO Capital's July 6 trim from $148 to $143 (still Outperform). UBS upgraded to Buy in late May with a $130 target. The street is broadly constructive, but the gap between targets and price reflects months of underperformance.
Data Summary
- Stock: $107.43, +5.8% on July 22; flat over one month
- Options PCR: 0.2949, z-score 3.53 — 52-week high defensiveness
- Insider activity: 8 executives sold July 17 at $105.08, including CEO ($401K) and CFO ($119K)
- Short interest: 2.8% of float, down 16% week-on-week
- Borrow availability: 7,757% — extremely loose
- Cost to borrow: 0.45%, up 56% in one week
- Consensus target: $129.57; next earnings July 24
Stocks in this article
See the live data behind this article on ORTEX.
Open RPM on ORTEX →How this article was generated
- Generated
- 23 Jul 2026, 11:25
- Data as of
- 23 Jul 2026, 11:19
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.